Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-
BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-
Does Semaglutide Cause Headaches? The Facts
Headache is a recognized side effect, but the timing alone doesn't explain it. The trial rates, possible triggers, and symptoms that need prompt care.
-
SELECT Trial Semaglutide Results: What 20% Means
SELECT recorded fewer major heart and blood-vessel events with branded semaglutide. Here is what the 20% headline means, who was studied, and where the evidence stops.
-
Semaglutide and Antidepressants: Can They Mix?
An antidepressant alone does not rule out semaglutide. The useful questions are how tablets are absorbed, how mood is doing, and what each medicine means for weight.
-
Should I Take Semaglutide? How a Provider Decides
A BMI of 32 can open the conversation. Medical history, current medicines and a workable follow-up plan determine where it goes.
-
Who Discovered Kisspeptin? The People Behind It
Danny Welch's cancer research started the story in 1996. Other teams found the peptide, connected it to puberty, and brought it into human studies.
-
FDA Category 2 Bulk Drug Substances: What It Means
Category 2 means FDA has identified significant safety concerns about a nominated compounding ingredient. Here is what the category tells a patient, and why leaving it does not mean approval.
-
Gray Market Peptides: What Johns Hopkins Found
Johns Hopkins says the market for unverified peptide vials is growing much faster than the human evidence. The useful question is what a prescription and a pharmacy change.
-
BPC-157 Myths: 10 Claims Checked
Ten familiar claims about BPC-157, graded against the studies: what comes from rats, what has been observed in people, and what remains unknown.
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
Sermorelin Clinical Trials: What the Studies Show
The 11-man study is real. Its results are narrower than the sales pitch, and later studies add evidence without settling the big claims.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
Who Discovered MOTS-c? The 2015 USC Discovery
Changhan Lee, Pinchas Cohen, and their colleagues reported MOTS-c in 2015. Its history runs from an overlooked genetic sequence to human observations and an ongoing question about treatment.
-
Forzinity Approval: One Year Later
On September 19, 2025, Forzinity became the first treatment for Barth syndrome through accelerated approval. A year later, that narrow decision still rests on a required confirmatory trial.
-
Is GHK-Cu FDA Approved? No, Its Review Is Pending
GHK-Cu is not FDA-approved. Its compounding review separates non-injectable use from injections, and the next advisory meeting still has no specific date.
-
503B Outsourcing Facility: What the Term Means
A 503B facility can prepare compounded medicines for clinic stock under federal manufacturing rules. Its registration describes the facility, not a review of each medicine.
-
BPC-157 Human Studies: What the Evidence Shows
Human evidence exists, but it is much smaller than online summaries make it sound: a few short, uncontrolled reports cannot establish that BPC-157 works or is safe long term.
-
10 Questions to Ask Doctor About Tirzepatide
A tirzepatide visit is mostly about fit: the provider needs a clear picture of medical history, medicines, pregnancy plans, digestion, and upcoming procedures. These ten questions explain what matters and why.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
Page 1 of 12 · 227 articles